TROPHY-U-01 Cohort 7: SG + EV + zimberelimab demonstrated promising efficacy (ORR 81%, n=21).

Back to meeting Original

Back to meeting

Kohji Takemura, MD· @KohjiToncol · X·2026-10-23 20:06· 2 days agoScore70

zimberelimab

Body

TROPHY-U-01 Cohort 7: SG + EV + zimberelimab demonstrated promising efficacy (ORR 81%, n=21).

Looking forward to results from larger phase II/III trials!

#ESMO26

53 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

4742Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

Sacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7

https://esmocongress.esmo.org

Source: Kohji Takemura, MD · x.com